Alirocumab's ODYSSEY continues into once-monthly dosing territory
This article was originally published in Scrip
Executive Summary
Sanofi and Regeneron have announced positive top-line Phase III data for their investigational PCSK9 inhibitor alirocumab when dosed every four weeks, narrowing what little gap there was between it and its main rival Amgen's evolocumab.